Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HRS-1167 + M1774 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HRS-1167 | M-9466|M 9466|HRS1167|HRS 1167|M9466 | PARP-1 Inhibitor 13 | HRS-1167 inhibits PARP1, which potentially reduces tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 3154)). | |
| M1774 | M-1774|M 1774|tuvusertib | ATR Inhibitor 16 | M1774 inhibits ATR, potentially resulting in decreased tumor growth (PMID: 38407317). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06421935 | Phase I | HRS-1167 + M1774 HRS-1167 Abiraterone + HRS-1167 + Prednisone | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | Recruiting | USA | ESP | AUS | 2 |